目的分析头孢他啶钠联合阿奇霉素治疗小儿肺炎支原体肺炎的临床效果及安全性。方法将收治的小儿肺炎支原体肺炎患儿134例作为研究对象,随机分为对照组67例,仅采取常规阿奇霉素治疗;观察组67例,采取头孢他啶钠联合阿奇霉素治疗。观察患儿症状改善时间,记录炎性指标血清C反应蛋白(CRP)变化,评估用药疗效及不良反应。结果观察组患儿在发热消退时间、肺部湿啰消退时间、咳嗽喘息消失时间及住院时间均明显少于对照组患儿,差异有统计学意义(P<0.05);观察组患儿CRP水平降低幅度显著高于对照组患儿,差异有统计学意义(P<0.05);观察组患儿治疗总有效率97.01%显著高于对照组患儿治疗总有效率80.60%,差异有统计学意义(P<0.05);全部患儿在用药期间均未出现严重不良反应症状,观察组患儿不良反应发生率明显低于对照组患儿,差异有统计学意义(P<0.05)。结论头孢他啶钠联合阿奇霉素治疗小儿肺炎支原体肺炎疗效确切,能够短期缓解炎性反应,抑制病情恶化,改善症状,减少患儿用药不良反应发生,具有极高的治疗安全性。 Objective To analyze the clinical efficacy and safety of ceftazidime sodium combined with azithromycin in the treatment of children with Mycoplasma pneumoniae pneumonia. Methods 134 children with mycoplasma pneumoniae pneumonia admitted to our hospital were randomly divided into control group (67 cases) and conventional azithromycin treatment group (67 cases). Ceftazidime sodium combined with azithromycin was used in the study group. Observe the symptoms of children to improve time, record the changes of inflammatory index serum C-reactive protein (CRP), evaluation of drug efficacy and adverse reactions. Results The observation group children in the fever subsided time, lung wetness subsided time, cough and wheezing disappear time and hospitalization time were significantly less than control children, the difference was statistically significant (P <0.05); observation group children with CRP levels (P <0.05). The total effective rate in treatment group was 97.01%, which was significantly higher than that in control group (80.60%), the difference was statistically significant (P0.05) .There was no serious adverse reactions in all the children during the medication, the incidence of adverse reactions in the observation group was significantly lower than that in the control group, the difference was statistically significant (P <0.05). Conclusion Ceftazidime sodium combined azithromycin treatment of children with Mycoplasma pneumoniae pneumonia exact effect, can short-term relief of inflammatory response, inhibition of disease progression, improve symptoms and reduce adverse reactions in children with high safety of treatment.